-+ 0.00%
-+ 0.00%
-+ 0.00%

Bio-Techne FY26 net earnings more than doubled to $240.68 million; net sales slip 0.38% to $1.22 billion

PUBT·08/24/2026 20:32:16
Listen to the news
Bio-Techne FY26 net earnings more than doubled to $240.68 million; net sales slip 0.38% to $1.22 billion
  • Bio-Techne fiscal 2026 net earnings climbed to USD 240.68 million, while net sales were flat at USD 1.22 billion.
  • GAAP gross margin widened 1 percentage point to 65.8%.
  • Non-GAAP adjusted net earnings edged down 1% to USD 303.34 million, while adjusted gross margin narrowed 0.8 percentage point to 69.6%.
  • Agreement signed June 25 to merge with Merck KGaA; shareholders would receive USD 73 per share in cash at closing.
  • Deal expected to close in late 2026 or early 2027, subject to shareholder approval and regulatory clearances.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-100322), on August 24, 2026, and is solely responsible for the information contained therein.